About the Webinar
The discovery of small interfering RNAs (siRNAs) has revolutionized therapeutic development by enabling precise down-regulation of gene expression in human cells, offering significant potential to treat and potentially eradicate diseases.
Selecting optimal siRNAs for drug discovery and clinical development requires careful consideration early in the process.
This webinar delves into some key factors for selecting effective therapeutic siRNAs.
You’ll learn about integrating intellectual property and manufacturing with sequence selection and molecular design, leveraging machine learning for mRNA target selection and utilizing medicinal chemistry as a "toolbox" for siRNA lead optimization.
In this webinar, you will:
- Explore some key factors in siRNA selection and design
- Learn about machine learning applications in siRNA development
- Discover how applying medicinal chemistry can be applied in siRNA lead optimization
Meet the Speaker
Dr. Marie Wikström Lindholm
CSO of Silence Therapeutics
Dr. Marie Wikström Lindholm is the CSO of Silence Therapeutics, leading a skilled team focusing on fine-tuning design of GalNAc-conjugated siRNA and exploring extra-hepatocyte siRNA targeting.
Marie has a PhD in medical chemistry from Uppsala University, Sweden and was an associate professor in experimental cardiovascular medicine at Lund University before moving to industry.
In 2007, Marie joined the Danish biotechnology company Santaris Pharma, working on LNA oligonucleotide research. Santaris Pharma was acquired by Roche and Marie was appointed expert scientist in discovery technology and head of targeted delivery of oligonucleotide conjugates.
Marie has authored >60 patents and scientific publications, many in the fields of antisense drug design, safety and function.
If the video has not loaded above, please click here.
